Topics and Expertise: cancer

Altschuler and Wu develop new cell-screening approach to speed drug discovery

How do you discover new drugs against diseases such as cancer?

Kroetz leads new study of genetics of cancer drugs’ dose-limiting side effects

Taxanes are a class of drugs widely used to treat a variety of cancers, including breast, ovarian, lung, gastric, and head and neck. But dosages are often limited by toxic side effects—most commonly damage to the body’s peripheral nerves, causing numbness, pain, and/or hyper-sensitivity—that can...

Dorie Apollonio, PhD, MPP

Professor

My work considers the activities of industries implicated in the spread of non-communicable diseases, including tobacco, pharmaceuticals, cannabis, alcohol, and food. Some recent work has identified tobacco cessation strategies for vulnerable populations, sought to understand the scope of tobacco...

Francis Szoka, PhD

Professor

I work with the dean as well as the vice dean of academic affairs to develop new avenues for incentivizing faculty success and retention.

During my research career, I applied biophysics, chemistry, and immunology to understand and devise better ways to deliver drugs, proteins, and nucleic acids to...

Study builds breast tissues to track how abnormal cells affect neighbors

It can take just the flick of a genetic switch for breast cells to kick-start the normally well-regulated process of growth seen in puberty, pregnancy, or the menstrual cycle—or the mutation of that switch to initiate the unchecked proliferation of cancer.

Abate aided by QB3’s Startup in a Box program

Adam Abate, PhD, a faculty member in the UCSF Schools of Pharmacy and Medicine, Department of Bioengineering and Therapeutic Sciences, is a prime trial candidate for QB3’s Startup in a Box.

School of Pharmacy biotech symposium features case histories of future pharmaceuticals

The 2nd Annual Bay Area Biotechnology Symposium, presented by the UCSF School of Pharmacy’s Industry Outreach Program in coordination with the UCSF Postdoctoral Scholars Association at Mission Bay in late May 2011, fully lived up to its billing: “Pharmaceuticals of the Futur

UCSF technology used to trigger cell death becomes basis of company’s cancer therapy research and development

A technology developed in the laboratory of James Wells, PhD, chair of the Department of Pharmaceutical Chemistry, UCSF School of Pharmacy, will drive a new approach to cancer treatment that s

Wells uses small molecules to trigger cell death

Research directed by senior author James Wells, PhD, chair of the Department of Pharmaceutical Chemistry, UCSF School of Pharmacy, has opened the door to a new way of studying and better understanding the processes of cell death (apoptosis), blood clotting, and other biochemic

Study identifies lack of information about HER2 testing practices

Breast cancer patients might not be getting full advantage from a genetic screening test for the protein known as HER2 to help determine if the use of trastuzumab (marketed as Herceptin) is the best course of treatment for them. For patients whose breast cancer cells produce excessive amounts of...

Pages